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Abstract
Introduction: Induced pluripotent stem cells (iPSCs) are a potent cell source for neurogenesis. Previously we have
generated iPSCs from human dental stem cells carrying transgene vectors. These exogenous transgenes may affect
iPSC behaviors and limit their clinical applications. The purpose of this study was to establish transgene-free iPSCs
(TF-iPSCs) reprogrammed from human stem cells of apical papilla (SCAP) and determine their neurogenic potential.
Methods: A single lentiviral ‘stem cell cassette’ flanked by the loxP site (hSTEMCCA-loxP), encoding four human
reprogramming factors, OCT4, SOX2, KLF4, and c-MYC, was used to reprogram human SCAP into iPSCs. Generated
iPSCs were transfected with plasmid pHAGE2-EF1a-Cre-IRES-PuroR and selected with puromycin for the TF-iPSC
subclones. PCR was performed to confirm the excision of hSTEMCCA. TF-iPSC clones did not resist to puromycin
treatment indicating no pHAGE2-EF1a-Cre-IRES-PuroR integration into the genome. In vitro and in vivo analyses of
their pluripotency were performed. Embryoid body-mediated neural differentiation was undertaken to verify their
neurogenic potential.
Results: TF-SCAP iPSCs were generated via a hSTEMCCA-loxP/Cre system. PCR of genomic DNA confirmed
transgene excision and puromycin treatment verified the lack of pHAGE2-EF1a-Cre-IRES-PuroR integration.
Transplantation of the TF-iPSCs into immunodeficient mice gave rise to teratomas containing tissues representing
the three germ layers – ectoderm (neural rosettes), mesoderm (cartilage and bone tissues) and endoderm
(glandular epithelial tissues). Embryonic stem cell-associated markers TRA-1-60, TRA-2-49 and OCT4 remained
positive after transgene excision. After neurogenic differentiation, cells showed neural-like morphology expressing
neural markers nestin, bIII-tubulin, NFM, NSE, NeuN, GRM1, NR1 and CNPase.
Conclusions: TF-SCAP iPSCs reprogrammed from SCAP can be generated and they may be a good cell source for
neurogenesis.
Introduction
Stem cells from apical papilla (SCAP) are derived from the
developing tissue at the apex of a tooth root termed apical
papilla [1,2]. These cells exhibit mesenchymal stem cell
(MSC) properties with multi-lineage differentiation poten-
tial and they express several neural markers when grown
in neurogenic cell culture, including bIII-tubulin, glutamic
acid decarboxylase (GAD), NeuN, nestin, neurofilament
medium chain (NFM), neuron-specific enolase (NSE), and
2’, 3’-cyclic nucleotide-3’-phosphodiesterase (CNPase)
[2,3]. SCAP are considered a type of cell source for odon-
toblasts responsible for root development and they are
capable of regenerating pulp and dentin tissues in vivo [4].
SCAP are highly robust in terms of relatively high popula-
tion doubling and telomerase activities [1,2]. We have pre-
viously shown that three types of dental stem cells, SCAP,
DPSCs (dental pulp stem cells) and SHED (stem cells
from human exfoliated deciduous teeth) can be easily
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reprogrammed into induced pluripotent stem cells (iPSCs)
at a higher reprogramming rate than dermal fibroblasts
using Thomson’s four factors, LIN28, NANOG, OCT4 and
SOX2 and their vector system [5].
iPSCs have tremendous medical applications and are
very similar to embryonic stem cells (ESCs) [6,7]. How-
ever, it was realized that iPSCs generated by viral vector
transduction either using Yamanaka’s four factors,
c-MYC, KLF4, OCT4, SOX2 [8,9] or Thomson’s four fac-
tors prevent iPSCs from being more similar to ESCs
because the transgene-carrying iPSCs have a different
profile at global gene expression and epigenetic levels,
and have altered differentiation into functional cell types
[10-12]. Furthermore, it is obvious that carrying onco-
genes such as c-MYC raises a safety concern for their
clinical use [13-16].
Tremendous efforts have been made to deliver the
reprogramming factors without viral vector integration.
The approaches include transient expression using adeno-
viral or nonviral vectors [17,18], removing the integrated
vectors using piggyBac transposition [19,20], minicircle
DNA [21], and non-integrating episomal vectors
[15,22,23]. However, the reprogramming efficiencies both
in human or mouse systems were very low ranging from
0.00005% to 0.039% and most cases were at the lower end.
The approach of non-integrating episomal vectors
reported by Yu et al. [22] required three individual plas-
mids carrying a total of seven factors, including the onco-
gene SV40, and has not been shown to reprogram cells
successfully from adult donors. Using recombinant pro-
tein-based four factors [24,25], synthesized mRNA [26],
and Sendai virus [27] to generate iPSCs has also been
reported. Unfortunately, the protein transduction method
is extremely difficult, labor-intensive and time-consuming
at present, and modifying Sendai virus vectors or prepar-
ing synthesized RNA is technically demanding.
Recently, a single lentiviral ‘stem cell cassette’
(STEMCCA) carrying all four Yamanaka’s factors was
developed for the efficient generation of iPSCs from
mouse postnatal fibroblasts [28]. Subsequently, the
STEMCCA was modified into an excisable single polycis-
tronic vector containing loxP sites. Most importantly, the
excision of the vector system after reprogramming
improved the iPSC differentiation potential [29]. The
STEMCCA-loxP was then humanized to carry four
human reprogramming factors, OCT4, SOX2, KLF4, and
c-MYC (designated as hSTEMCCA-loxP) and has been
shown to reprogram human fibroblasts successfully [30].
This excisable single polycistronic vector system provides
a high efficiency in reprogramming fibroblasts into iPSCs
(mouse: 0.5%; human: 0.1% to 1.5%). To utilize iPSCs for
clinical applications or to understand the biology of these
cells, removal of exogenously introduced genes in these
cells is a critical step, given the premise that iPSCs are
independent of exogenous reprogramming transgene
expression and retain their pluripotency following factor
withdrawal. Using the single vector STEMCCA and Cre/
loxP system, transgene-free (TF) iPSCs can be generated
which possess pluripotent characteristics [29,30]. In the
present study, we applied this system and technology to
generate TF iPSCs from SCAP and examined their
neurogenic potential as the first step toward generating




Human SCAP primary cultures were established as pre-
viously described [2]. In brief, freshly extracted teeth were
collected from healthy donors (16- to 24-years old) in the
Oral Surgery Clinics at Boston University based on an
exempt protocol approved by the Boston University Medi-
cal Institutional Review Board (#H-28882). Apical papilla
from immature permanent teeth were minced and digested
in a solution of 3 mg/mL collagenase type I and 4 mg/mL
dispase (Sigma-Aldrich, St. Louis, MO, USA) for 30 to 60
minutes at 37°C. The digested mixtures were passed
through a 70-μm cell strainer (Falcon, BD Labware, Frank-
lin Lakes, NJ, USA) to obtain single cell suspensions. Cells
were seeded into six-well plates and cultured with a-mini-
mum essential medium (a-MEM; Life Technologies/Invi-
trogen, Grand Island, NY, USA) supplemented with 15%
fetal bovine serum (FBS; Gemini Bio-Products, Inc., Wood-
land, CA, USA), 2 mM L-glutamine, 100 μM L-ascorbic
acid-2-phosphate, 100 U/mL penicillin-G, 100 mg/mL
streptomycin, and 0.25 mg/mL fungizone (Gemini Bio-Pro-
ducts, Inc., West Sacramento, CA, USA) and maintained in
5% CO2 at 37°C. Colony formation units of fibroblastic
cells (CFU-F) were normally observed within 1 to 2 weeks
after cell seeding and were passaged at a 1:3 ratio when
they reached approximately 70% confluence. Heteroge-
neous populations of SCAP were frozen and stored in
liquid nitrogen at passages 0 to 2 (p0 to p2). Cells were
thawed and expanded for experimentation. These heteroge-
neous populations of adherent, clonogenic dental stem/pro-
genitor cells were routinely tested for their cell surface
marker expression with flow cytometry and they were posi-
tive for STRO-1, CD146, CD73, CD90, and CD105 and
negative for CD14, CD34, and CD45, which are typical fea-
tures of MSCs [3]. Mouse embryonic fibroblasts (MEFs)
were used as the feeder cells isolated from E13.5 embryos
of CF1 pregnant mice according to the NIH standard pro-
tocol [31] and cultured in (D)MEM supplemented with
10% FBS. All animal procedures followed a protocol
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) at Boston University (protocol# AN15026).
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Transduction and reprogramming of SCAP
Lentiviruses were produced in 293T packaging cells with
five plasmid cotransfection, concentrated by ultracentrifu-
gation and titered as previously described [29,30]. Viral
titers of approximately 1 × 108 TU (transducing unit)/ml
were employed for reprogramming experiments. Hetero-
geneous primary human SCAP at p3 were transduced
with lentiviral vectors hSTEMCCA-loxP (a polycistronic
single vector carrying all four human reprogramming fac-
tors, c-MYC, KLF4, OCT4 and SOX2) in the presence of
polybrene (5 μg/mL). Within six days, 4 × 104 transduced
SCAP were trypsinized and seeded onto mitomycin C-
-inactivatedMEFs on a 10-cm gelatin-coated culture dish.
The next day, the medium was changed to human
embryonic stem cell (hESC) medium (80% (D)MEM/F12,
20% knock-out serum replacement, 1x non-essential
amino acid, 1 mM L-glutamine, 0.1 μM b-mercaptoetha-
nol) containing 4 ng/mL basic fibroblast growth factor
(bFGF). Within two weeks, a few cell colonies resembling
ESC colonies began to emerge (they were considered as p0
prospective iPSCs). Emerged colonies were manually
isolated/passaged 28 days post-viral vector transduction
and expanded on MEF feeders in hESC medium. Each col-
ony was manually subcloned and grown/expanded sepa-
rately into wells of 12-well plates. The expanded SCAP
iPSCs at p2 were used for further Cre-mediated excision
of hSTEMCCA.
Excision of hSTEMCCA
The transfection of SCAP-iPSC colonies for the excision
of the transgene/vector was performed using the Hela
Monster transfection reagent (Mirus, Madison, WI, USA)
according to the manufacturer’s instructions. Briefly, 60%
to 70% confluent p2 SCAP iPSCs were cultured on puro-
mycin resistant MEFs (DR4 MEF, GlobalStem, Rockville,
MD, USA) in six-well plates. The cells were then exposed
to 2.5 mL/well hESC medium containing 4 ng/mL bFGF,
2.5 μg pHAGE2-Cre-IRES-PuroR plasmid DNA, 7.5 μl
Trans IT Hela reagent and 5 μl MONSTER reagent. After
24 hours, the medium was changed to hESC medium and
the cultures incubated for about an additional 6 hours,
after which selection of the transfected SCAP iPSCs with
puromycin (1.2 μg/mL) began and lasted for 48 hours.
The medium containing puromycin was changed every 24
hours. Fresh hESC medium was used after puromycin
treatment and changed daily. New SCAP iPSC colonies
re-emerged in two to four days. On days 11 to 14, five
newly emerged colonies from each well were picked and
transferred into new MEFs plates and grown/expanded
individually. Genomic DNA from each subclone was
extracted and PCR performed to verify for the excision
of the hSTEMCCA. The primers used and the PCR condi-
tions are as follows: c-MYC (forward primer): 5’ -GGA
ACT CTT GTG CGT AAG TCG ATA G-3’; WPRE
(reverse primer) 5’-GGA GGC GGC CCA AAG GGA
GGA GAT CCG-3’; 95°C for 3 minutes; followed by 33
cycles of 94°C for 30 seconds, 60°C for 30 seconds and 72°
C for 5 minutes. The PCR products were examined by
electrophoresis on an agarose gel. Verified transgene free
clones were named TF-SCAP iPSCs.
To verify that there was no integration of pHAGE2-
Cre-IRES-PuroR plasmid DNA into the genome of TF-
SCAP iPSCs, these cells were grown on DR4 MEFs in
the presence of puromycin (1.2 μg/mL). Total cell death
indicated the lack of plasmid integration.
Immunocytofluorescence
iPSC colonies grown on MEFs in 12-well plates were fixed
in 100% ice cold methanol, incubated in blocking buffer
(32.5 mM NaCl, 3.3 mM Na2HPO4, 0.76 mM KH2PO4,
1.9 mM NaN3, 0.1% (w/v) BSA, 0.2% (v/v) Triton X-100,
0.05% (v/v) Tween 20, and 5% goat serum) for 30 minutes
followed by the addition of the following antibodies for
1 hour at room temperature: mouse anti-human TRA-1-
60, TRA-2-49 (both from Chemicon/Millipore, Temecula,
CA, USA) and OCT4 (Santa Cruz Biotech., Santa Cruz,
CA, USA). After washing, cultures were incubated with
anti-mouse antibodies Alexa Fluor 594 (Invitrogen) for
1 hour at room temperature and the cell nuclei stained
with 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen).
Images were analyzed under a fluorescence microscope.
Teratomas formation
SCAP iPSCs and TF-SCAP iPSCs at approximately 70%
confluence in a six-well plate were harvested by collagenase
IV treatment, collected into tubes, centrifuged, and the pel-
lets resuspended in the (D)MEM/F12 and Matrigel (3:1)
solution. The resuspended cells were injected intramuscu-
larly into the right and/or left hind legs of a SCID mouse
(SCID, NOD.CB17-Prkdc-scid/J; Jackson Laboratory, Bar
Harbor, ME, USA). Seven to nine weeks after injection,
tumors were resected, fixed with PBS containing 4% paraf-
ormaldehyde and processed. Paraffin-embedded tissue was
sectioned and stained with H & E for histologic analysis.
Neurogenic differentiation in vitro of TF- SCAP iPSCs
TF-SCAP iPSC colonies were grown on Matrigel with
TESR2 medium (Stemcell Technology, Vancouver, BC,
Canada). Subsequently, iPSC colonies were treated with
dispase (1 mg/mL) for seven minutes, resuspended in (D)
MEM/F12 supplemented with 20% FBS and 2 mM gluta-
mine. The colonies were collected and plated into Ultra
Low six-well plates to form embryoid bodies (EBs) for
four days. EBs were collected and plated into Matrigel-
coated wells of six-well plates. After cell attachment,
the medium was changed to neurogenic differentiation
medium ((D)MEM supplemented with B27 and 20 ng/mL
bFGF). The cells were incubated in the differentiation
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medium for eight days and subsequently stained for the
neural markers bIII-tubulin (TUJ1; Sigma-Aldrich), nestin
(Millipore) and neurofilament medium chain (NFM; Invi-
trogen). Cells were fixed in 100% ice cold methanol for 20
minutes and washed with PBS 3 times. Triton X-100
(0.1%) was applied to permeabilize the cells for 15 minutes
followed by washing with PBS 3 times. Fixed cells were
blocked with 5% goat serum for 1 hour. Primary mouse
monoclonal antibodies to human bIII-tubulin, nestin and
NFM (all at1:200) were applied and incubated at 4°C over-
night. After washing with PBS 3 times, secondary goat
anti-mouse Alexa Fluor 594 antibodies (Invitrogen) were
added and incubated at room temperature for 1 hour, and
cell nuclei were stained with DAPI (1:10,000) (Invitrogen)
[5]. Staining was examined under a fluorescence micro-
scope. RT-PCR analysis of neurogenic gene expression
was performed. Total RNA was isolated using RNeasy
Mini Kit (Qiagen, Vaenicia, CA, USA) from TF-SCAP
iPSCs grown on Matrigel with TESR2 medium and
neural-like cells after neurogenesis. cDNA was synthesized
with a SuperScript III RT-PCR kit (Invitrogen) followed by
PCR using Taq DNA Polymerase (Invitrogen) to detect
the human neural gene expression listed in Table 1.
Results
Generation of transgene-free SCAP iPSCs
Primary human SCAP showing typical fibroblast morphol-
ogy were transduced with lentiviral vectors hSTEMCCA
(Figure 1A) and seeded onto MEFs. Within one to two
weeks after transduction, ESC-like colonies emerged on
MEFs (Figure 1B). The rate of formation of ESC-like clones
was 0.11% ± 0.01 (% number of ESC-like colonies/number
of seeded transduced cells) based on four independent
experiments using SCAP from two different donors.
Before transfection of Cre-IRES-PuroR plasmids,
SCAP iPSCs showed typical hESC morphologies. After
transfection and 48 hours of puromycin treatment, most
of the colonies underwent cell death. Within two to
four days of recovery, newly emerging colonies were
observed around the margin of the original colonies, as
indicated in Figure 1C. The PCR results demonstrated
the deletion of hSTEMCCA vector. In three repeated
experiments, using SCAP iPSCs from different clones,
100% deletion of hSTEMCCA vector was found in these
newly emerged subclones (Figure 1D).
To determine whether there was integration of
pHAGE2-Cre-IRES-PuroR plasmid DNA into the genome
of TF-SCAP iPSCs, these cells were grown on DR4 MEFs
in the presence of puromycin (1.2 μg/mL) for up to a
week. On day two after the addition of puromycin, TF-
SCAP iPSCs underwent cell death leaving behind an
empty space in the DR4 MEF cultures (Figure 1E). No new
iPSC colonies emerged after seven days of observation,
indicating that TF-SCAP iPSCs contained no pHAGE2-
Cre-IRES-PuroR plasmid DNA in their genome.
Protein expression of hESC associated gene markers
Following Cre-mediated transgene excision, we assessed
the expression of hESC-associated genes. Immunocyto-
fluorescence analysis indicated that SCAP iPSCs
Table 1 Primers for RT-PCR.
Gene GenBank Accession Primer (5’— 3’) Product size (bp)
Forward
Reverse
Nestin NM_006617 AAC AGC GAC GGA GGT CTC TA
TTC TCT TGT CCC GCA GAC TT
220
bIII-tubulin NM_001197181 CAG ATG TTC GAT GCC AAG AA
GGG ATC CAC TCC ACG AAG TA
164
NFM NM_005382 CGA CCT CAG CAG CTA CCA GGA CAC
CAG TGA TGC TTC CTG CAA ATG TGC T
200
NSE NM_001975 GTC CCA CGT GTC TTC CAC TT
TGG GAT CTA CAG CCA CAT GA
236
NeuN NM_001082575 CTT ACG GAG CGG TCG TGT AT
AGA AGG AAA CGG TGG AAG GT
215
GRM1 NM_000838 TGA GGG TTG TCC CTT CTG AC
GGA AGC CTC TCT CGG AGT TT
241
NR1-1 NM_000832 AAG CCT CGA GGG TAC CAG AT
AGC TTG ATG AGC AGG TCG AT
236
CNPase NM_033133 GTG GAG CAC AAA AGC CTC TC
AAG TTT CCC ATG TGG CTG AC
232
GFAP NM_001131019 GCA GAT TCG AGG GGG CAA AA
GAA CTC AGG GGG ATT GGG AG
221
GAPDH NM_002046 CAA GGC TGA GAA CGG GAA GC
AGG GGG CAG AGA TGA TGA CC
194
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Figure 1 Generation of transgene-free SCAP iPSCs. (A) Schematic representation of the hSTEMCCA-loxP lentiviral vector integrated into the
human cell genome (h-genome) after transduction of SCAP. A loxP site was introduced within the U3 region of the 3’ LTR. Following the exposure
of pHAGE2-Cre-IRES-PuroR plasmid, the entire cassette was excised. (B) Emergence of SCAP iPSCs during reprogramming. (B-a) SCAP at passage (p)
0 before transduction. (B-b) SCAP at p3 were transduced with hSTEMCCA-loxP lentiviral vector and seeded onto MEF. A small ESC-like colony
emerged on day nine post transduction. (B-c) A SCAP ESC-like colony on day 28 post transduction on MEFs. The ESC-like colony is considered at
p0. (scale bar: 500 μm). (C) Excision of hSTEMCCA. (C-a) Established SCAP iPSC colonies at p2 before transgene excision. (C-b) After pHAGE2-Cre-
IRES-PuroR plasmid transfection and 48 hours of pluromycin treatment, most SCAP iPSC colonies died out leaving behind an empty space (arrow).
(C-c) New colonies (arrow) emerged on day 1 after Cre-excision and puromycin selection. (C-d) Expanded SCAP iPSC colonies passaged twice after
Cre-excision. (scale bar: 500 μm). (D) Excision of hSTEMCCA was verified by RT-PCR. Clones after cre-excision showed no detectable hSTEMCCA.
GAPDH served as a control. (E) A clone of TF-SCAP iPSCs grown on DR4 MEFs was treated with puromycin (1.2 μg/mL) for up to a week. (Ea) Before
the addition of puromycin. (Eb) On day 2 after the addition of puromycin. (Ec) On day 4 after puromycin treatment. (scale bar: 250 μm). ESC,
embryonic stem cells; iPSCs, induced pluripotent stem cells; MEF, mouse embryonic fibroblasts; SCAP, stem cells from apical papilla.
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expressed TRA-1-60, TRA-2-49, and OCT4 before and
after excision of hSTEMCCA, as shown in Figure 2.
Teratoma formation
To test the pluripotency of TF-SCAP iPSCs in vivo, ter-
atoma formation analysis was performed. As demon-
strated in Figure 3, both SCAP iPSCs before and after
hSTEMCCA excision formed teratomas in SCID mice.
They developed into primitive tissues representing all
three germ layers including neural tissues (ectoderm),
cartilage and bone (mesoderm), and glandular or
respiratory epithelial-like layers (endoderm). There were
numerous ectodermal neuroepithelial-like tissues includ-
ing pigmented retinal epithelium-like tissues as well as
glandular structures. These teratoma histologic images
presented in Figure 3 are typical primitive tissues repre-
senting the three germ layers. Immunohistochemical
staining to target specific germ layer markers is pre-
sented in Additional file 1 describing the Materials and
Methods and Additional file 2, Figure S1, showing
the expression of the ectoderm marker bIII-tubulin,
mesoderm marker a-smooth muscle actin (aSMA) and
endoderm marker AFP in teratomas formed by our pre-
viously generated SHED iPSCs that carried Thomson’s
four factors [5]. The immune-stained tissues shown in
the Supplemental Figure 1 in Additional file 2, especially
those that represent endodermal (glandular) and ecto-
dermal (neural) tissues, indicate that the teratoma tis-
sues presented in Figure 3 are typical tissues of the
three germ layers.
In vitro neural differentiation
The TF-SCAP iPSCs were tested for their neurogenic
potential using an EB-mediated protocol. Under the sti-
mulation of a neurogenic medium, cells from the EBs
developed into neural rosette morphology. These neural
rosettes formed in cultures highly resembling those
neural tissues formed in teratomas. Neural tube-like
Figure 2 Expression pluripotency markers by SCAP iPSCs in vitro. Embryonic stem cell-associated genes TRA-1-60, TRA-2-49 and OCT4
expressed by SCAP iPSCs before and after Cre-excision. Before Cre: SCAP iPSC clone 1 at passage (p)15. After Cre: SCAP iPSC-Cre clone1 at p12.
Expressed genes stained in red; DAPI, nuclear stain. (scale bar: 100 μm for all staining images). DAPI, 4’,6-diamidino-2-phenylindole; iPSCs,
induced pluripotent stem cells; SCAP, stem cells from apical papilla.
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structures consisting of columnar cells aligned as pali-
sades, that also frequently appeared in teratomas (Figure
3B-a,b; Figure 4A-b,c), were observed. At a higher magni-
fication, individual cells with elongated cellular processes
similar to axon structures could be identified (Figure 4A-
d). To determine whether these cells that morphologi-
cally resembled neuronal cells expressed neuronal genes,
cells were stained with the neural stem cell marker nes-
tin, early stage neuronal marker bIII-tubulin and mature
stage neuronal marker NFM. As shown in Figure 4B, the
neural rosettes or some cell aggregates were positive for
nestin or NFM, and the elongated cytoplasmic processes
were positive for bIII-tubulin, indicating the neurogenic
potential of TF-SCAP iPSCs.
We determined a number of neural markers with RT-
PCR. We first passaged iPSCs into MEF-free Matrigel
plates before undergoing EB formation to avoid MEF
contamination. We tested the RT-PCR using MEF RNA
and found that some human neural gene primers can
amplify mouse genes. Using MEF-free cultures elimi-
nated/reduced such possibilities. The results presented in
Figure 5 show that several neuron associated genes, bIII-
tubulin, NFM and NSE were already expressed in SCAP
without neurogenic induction. After reprogramming into
iPSCs, these genes remain expressed and their levels did
not appear to have a noticeable increase. NeuN was not
detected in SCAP while it dramatically increased after
becoming iPSCs with or without neurogenic induction.
Figure 3 Histological analysis of teratomas. Images of removed teratomas from mice are shown on the left of the image panels. (A) Multi-
differentiated tissues derived from SCAP iPSCs (passage (p)11) before Cre-excision. (B) Teratomas from SCAP iPSCs (p10) after Cre-excision. (A &
B) (a,b) mainly neural tissues, neural rosettes (ectoderm); (c) mainly cartilage (mesoderm); (d) bone tissue (mesoderm); (e,f) mainly glandular
epithelium and endodermal tissues. (scale bar: 100 μm for all histologic images. Except Bf, all histologic images use the scale bar in Ba). iPSCs,
induced pluripotent stem cells; SCAP, stem cells from apical papilla.
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Nestin was barely detectable in SCAP while its expression
increased after becoming iPSCs and remained detectable
after neurogenic induction. Glutamate receptors gluta-
mate receptor, metabotropic 1 (GRM1) and glutamate
receptor, ionotropic, N-methyl D-aspartate 1 (NR1-1)
could not be detected in SCAP but were detectable after
becoming iPSCs. GRM1 was expressed in iPSCs with or
without neurogenic induction and NR1-1 was only
detectable after induction. The glia cell marker genes
CNPase and glial fibrillary acidic protein (GFAP) are
regulated differently in SCAP and SCAP iPSCs. CNPase,
as the oligodendrocyte marker, was slightly expressed in
SCAP and the level became elevated when turning into
iPSCs. The expression level appeared to further increase
slightly after neurogenic induction. GFAP, the astrocyte
marker, on the other hand, was not detected in SCAP
and SCAP iPSCs (with or without induction).
Discussion
The present study demonstrated a successful generation
of TF-SCAP iPSCs characteristic of typical iPSCs cap-
able of teratoma formation and neurogenic differentia-
tion. Using the polycistronic hSTEMCCA-loxP vector
carrying all four reprogramming genes, we were able to
consistently reprogram SCAP into iPSCs and remove
the transgene/vector with a Cre-mediated approach.
We previously generated iPSCs from dental stem cells
including SCAP using either the Thomson’s four repro-
gramming factors (human) with the viral vector system
pSin-EF2-gene-Pur each carrying one of the four factors
LIN28, NANOG, OCT4, and SOX2; or the Yamanaka’s
four factors (human) c-MYC, KLF4, OCT4 and SOX2
each into the vector pMXs [5]. While these dental iPSCs
demonstrated typical iPSC characteristics including tera-
toma formation, they have unfavorable features when
being guided into certain differentiation pathways.
These transgene-carrying iPSCs (pSin-EF2-gene-Pur vec-
tor system) underwent massive cell death (data not
shown) after differentiation toward MSC lineages using
a reported protocol established for deriving MSCs from
hESCs [32]. We used the same protocol to guide hESCs
(H1 and H9) and were successful in generating MSC-
like cells without witnessing any cell death phenom-
enon. Furthermore, the survival rate of these transgene-
carrying dental iPSCs was extremely low after freezing
and thawing. Most of the frozen-down dental iPSCs
generated using the pSin-EF2-gene-Pur vector system
did not survive after thawing. In contrast, TF-SCAP
iPSCs were able to recover better after freezing/thawing
and they were able to differentiate into MSC lineages
without cell death (data not shown). Earlier when we
attempted reprogramming dental stem cells using the
Figure 4 EB-mediated neural differentiation of TF-SCAP iPSCs in vitro. (A-a to Ad) Four-day-old EBs were plated into Matrigel-coated wells
of six-well plates. On day 8 after neurogenic stimulus, differentiated iPSCs developed into neural rosette morphology. Some cells extended
elongated cell cytoplasmic processes resembling axons. (scale bar: 100 μm for all images in A) (B) Immunofluorescence analysis of differentiated
neural-like cells showing positive staining of neuronal marker bIII-tubulin (TUJ1). Cells forming a neural rosette or spherical morphology were also
positive for nestin and NFM. Expressed genes stained in red; DAPI, nuclear stain. (scale bar: 100 μm). DAPI, 4’,6-diamidino-2-phenylindole; EB,
embryoid body; iPSCs, induced pluripotent stem cells; SCAP, stem cells from apical papilla; TF, transgene free.
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pLenti6.2/C-Lumio/V5-DEST vector system containing a
CMV promoter [5], we also observed cell death phe-
nomenon. As we reported, this vector system never suc-
ceeded in generating iPSCs. Instead, it caused some cell
death at the very beginning, and those cells that sur-
vived turned into iPSC-like cells and then underwent
cell death also [6]. It is possible that the hSTEMCCA-
loxP vector is a good match for dental stem cell
reprogramming.
The reprogramming rate using hSTEMCCA-loxP is
higher than our previous attempts using pSin-EF2-gene-
Pur vectors. Using hSTEMCCA-loxP, we also repro-
grammed human foreskin fibroblasts (ATCC) and
human gingival fibroblasts (from one donor) and the
reprogramming rates were 0.016% and 0.07%, respec-
tively, based on one experiment. Reprogramming human
DPSCs in two independent experiments yielded us repro-
gramming rates of 0.6% and 0.083%. In our experimental
settings either using pSin-EF2-gene-Pur vectors pre-
viously or hSTEMCCA-loxP in the present studies, den-
tal stem cells have shown a higher reprogramming rate
than fibroblasts. One condition that favors the repro-
gramming efficiency is the division rate of the cells being
reprogrammed [33]. The high proliferation rate of dental
stem cells including SCAP and the polycistronic gene
cassette hSTEMCCA-loxP vector offer a high reprogram-
ming efficiency over existing multi-vector approaches for
skin fibroblasts [33]. It likely derives in part from favor-
able stoichiometry of the four reprogramming transcrip-
tion factors when expressed in this particular order by a
polycistronic system [15].
Following the generation of SCAP iPSCs via
hSTEMCCA-loxP, we applied a plasmid expressing Cre
to excise the reprogramming transgenes. Deletion of the
hSTEMCCA was found in 100% of these clones, indicat-
ing that Cre-mediated excision was very effective. Addi-
tional transfection of plasmids carrying Cre does not
lead to integration of the plasmid into the genome, veri-
fied by the observation that puromycin treatment of the
TF iPSC clones led to total cell death. It should be
noted, however, that an inactive fragment of the viral
long terminal repeat (LTR) remains in the host genome
after Cre-excision. Although highly unlikely, there may
theoretically be a risk of insertional mutagenesis. This
could be reduced by targeting the hSTEMCCA into a
safe genomic locus [30]. Further investigation would be
needed to find approaches which would obtain not only
transgene-free and completely vector-free iPSCs, but
also maintain a high reprogramming rate in order to
utilize iPSCs for clinical applications.
The SCAP iPSCs maintained their pluripotency after
Cre-excision as indicated by the in vitro expression of
ESC-associated gene markers and the teratoma forma-
tion which is consistent with previous studies [30]. TF-
SCAP iPSCs have been in continuous culture for six
months after the initial transduction and maintain a
morphology that is similar to hESCs. The iPSCs from
different cell types may be different in their abilities to
undergo guided differentiation directions [34], and
iPSCs were reported to retain a transcriptional memory
of their tissue of origin [35]. In addition, in our present
study along with our reported work [5], there were
numerous neuroepithelial-like tissues in teratomas
derived from both TF-SCAP iPSCs and SCAP iPSCs,
suggesting that iPSCs from SCAP may have robust
potential to differentiate into neural tissues. Our in vitro
neural differentiation studies indicated that TF-SCAP
iPSCs can be guided to form neural-like cells and
Figure 5 RT-PCR analysis of the expression of neural markers.
The neurogenic induction followed the same method as that for
samples shown in Figure 4. The SCAP are the original cells from
which TF-SCAP iPSCs were derived. GAPDH was used to ensure
equal loading of the samples. (+), presence of neurogenic induction
medium; (-), regular culture medium without neurogenic induction.
iPSCs, induced pluripotent stem cells; SCAP, stem cells from apical
papilla; TF, transgene free.
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express neural genes. It is interesting to find that the
expression of bIII-tubulin, NFM, NSE and NeuN was
already detectable at considerable levels at the pluripo-
tent state before neurogenic stimulus and there was no
noticeable increase after stimulation (at best, NFM had
a slight increase). The oligodendrocyte marker CNPase
was also detected in uninduced SCAP and its expression
was increased in SCAP iPSCs and further elevated after
induction. Dental stem cells including DPSCs and SCAP
express neural markers such as nestin and bIII-tubulin
in cultures without neurogenic stimulus [36,37]. It may
be that this gene expressing signature is retained after
being reprogrammed into iPSCs; however, it will be a
major undertaking to verify such a possibility. Although
the two glutamate receptors GRM1 and NR1-1 that
function at synapses to transmit neural signals were not
expressed in SCAP, they can be detected after being
reprogrammed into iPSCs or after neurogenic induction.
Taken together, our establishment of TF-SCAP iPSCs
and the initial confirmation of their neurogenic potential
using a simple neurogenic induction protocol warrant
further exploration of their abilities in neurogenesis as
well as neural tissue regeneration in vivo.
Conclusions
TF-iPSCs SCAP can be effectively and consistently gen-
erated using the hSTEMCCA-loxP vector system fol-
lowed by Cre-mediated excision. These TF iPSCs
maintain ESC characteristics and can differentiate into
neural-like cells expressing neural marker genes in vitro.
Further investigation will test whether they are a good
cell source for in vivo neural tissue regeneration.
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